01349.HK
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.51
+0.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 665.0M | 685.8M | 709.4M | 850.7M | 1.0B |
| Cost of Revenue | 84.2M | 69.3M | 61.2M | 70.6M | 84.1M |
| Gross Profit | 580.8M | 616.5M | 648.2M | 780.1M | 947.1M |
| Operating Expenses | |||||
| R&D Expense | 306.4M | 357.9M | 314.2M | 243.8M | 226.9M |
| SG&A Expense | 415.9M | 280.2M | 195.3M | 271.6M | 567.6M |
| General & Admin Expense | 10.3M | 19.6M | 19.5M | 16.1M | 12.9M |
| Selling & Marketing Expense | 72.9M | 260.6M | 175.8M | 255.6M | 554.6M |
| Other Expenses | 229.0M | 132.3M | 450.5M | 167.6M | 19.4M |
| Total Operating Expenses | 697.0M | 770.4M | 645.8M | 683.0M | 813.8M |
| Cost and Expenses | 781.2M | 841.2M | 707.0M | 753.6M | 897.9M |
| Operating Income (EBIT) | (129.6M) | (155.4M) | 2.4M | 97.1M | 133.3M |
| Non-Operating | |||||
| Interest Income | 17.0M | 17.6M | 5.5M | 8.0M | 11.3M |
| Interest Expense | 536.9K | 716.3K | 591.6K | 3.1M | 1.5M |
| Net Interest Income | 16.5M | 16.9M | 5.0M | 4.9M | 9.8M |
| Other Non-Op Income/Expense | 6.8M | (449.1K) | 3.1M | 438.4K | (977.9K) |
| Non-Operating Income (excl Interest) | — | — | (3.7M) | (3.5M) | (560.4K) |
| EBT (Pre-Tax Income) | (122.8M) | (155.9M) | 5.5M | 97.5M | 132.3M |
| Income Tax Expense | 2.1M | 1.9M | (34.0M) | (10.9M) | (5.0M) |
| Bottom Line | |||||
| Net Income | (124.1M) | (153.4M) | 39.7M | 108.6M | 138.0M |
| Earnings from Cont. Ops | (122.8M) | (157.7M) | 39.4M | 108.4M | 137.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (124.4M) | (153.4M) | 39.7M | 108.6M | 138.0M |
| Per Share | |||||
| Basic EPS | (HK$0.12) | (HK$0.14) | HK$0.04 | HK$0.11 | HK$0.13 |
| Diluted EPS | (HK$0.12) | (HK$0.14) | HK$0.04 | HK$0.11 | HK$0.13 |
| Revenue Per Share | HK$0.64 | HK$0.65 | HK$0.68 | HK$0.82 | HK$1.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Diluted Shares Outstanding | 1.0B | 1.0B | 1.0B | 1.0B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | (99.3M) | (81.5M) | 48.1M | 160.5M | 214.8M |
| D&A | 72.8M | 76.6M | 45.7M | 59.9M | 81.0M |
| EBIT | (131.7M) | (158.1M) | 2.4M | 100.6M | 133.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026